Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Qsymia sera

First Manhattan in charge of Qsymia after gaining control of Vivus board

Qsymia sera

Now that First Manhattan Co. is gaining control of Vivus Inc.'s board and the top management job, all eyes will be on whether the dissident shareholder's team can ramp up sales of obesity drug Qsymia. Neither party is

Read the full 397 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers